Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment

The treatment of liver cancer remains challenging due to the low responsiveness of advanced cancer to therapeutic options. Sorafenib is the first line chemotherapeutic drug for advanced liver cancer but is frequently associated with severe side effects lead to discontinuation of chemotherapy. We pre...

Full description

Bibliographic Details
Main Authors: Chen Zhang, Wu Zhong, Ying Cao, Bohao Liu, Xiaojun Tao, Zhuan Li
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Pharmaceuticals
Subjects:
polylysine
sorafenib
SIRT7 inhibitor
GSH-sensitive PEG
tumor microenvironment
targeted therapy
Online Access:https://www.mdpi.com/1424-8247/16/1/119

Internet

https://www.mdpi.com/1424-8247/16/1/119

Similar Items